Evaluation of influenza virus A/H3N2 and B vaccines on the basis of cross-reactivity of postvaccination human serum antibodies against influenza viruses A/H3N2 and B isolated in MDCK cells and embryonated hen eggs

Clinical and Vaccine Immunology

Volumn 19, Issue 6, 2012, Pages 897-908

  Kishida, Noriko ^a   Fujisaki, Seiichiro ^a   Yokoyama, Masaru ^a   Sato, Hironori ^a   Saito, Reiko ^b   Ikematsu, Hideyuki ^c   Xu, Hong ^a   Takashita, Emi ^a   Tashiro, Masato ^a   Takao, Shinichi ^d   Yano, Takuya ^e   Suga, Tomoko ^f   Kawakami, Chiharu ^g   Yamamoto, Miwako ^h   Kajiyama, Keiko ⁱ   Saito, Hiroyuki ^j   Shimada, ShiN'Ichi ^k   Watanabe, Sumi ^l   Aoki, Satomi ^m   Taira, Katsuya ⁿ   Kon, Miyako ^o   Lin, Jih Hui ^p   Odagiri, Takato ^a   more..

^a NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d HIROSHIMA PREFECTURAL TECHNOLOGY RESEARCH INSTITUTE   (Japan)

^e Mie Prefectural Health and Environment Research Institute   (Japan)

^f KOBE INSTITUTE OF HEALTH   (Japan)

^g Yokohama City Institute of Health   (Japan)

^h Hiroshima City Institute of Public Health   (Japan)

ⁱ Fukuoka City Institute for Hygiene and Environment   (Japan)

^j Akita Research Center for Public Health and Environment   (Japan)

^k SAITAMA INSTITUTE OF PUBLIC HEALTH   (Japan)

^l KANAGAWA PREFECTURAL INSTITUTE OF PUBLIC HEALTH   (Japan)

^m EHIME PREFECTURAL INSTITUTE OF PUBLIC HEALTH AND ENVIRONMENTAL SCIENCE   (Japan)

ⁿ OKINAWA PREFECTURAL INSTITUTE OF HEALTH AND ENVIRONMENT   (Japan)

^o Niigata Prefectural Institute of Public Health And Environmental Sciences   (Japan)

^p CENTER FOR DISEASE CONTROL   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; NEUTRALIZING ANTIBODY;

ADULT; AGE DISTRIBUTION; AGED; ANIMAL CELL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELL STRAIN; CONTROLLED STUDY; CROSS REACTION; DRUG EFFICACY; DRUG SCREENING; EMBRYO; HEMAGGLUTINATION INHIBITION TEST; HEN; HUMAN; INFLUENZA VACCINATION; INFLUENZA VIRUS A H3N2; NONHUMAN; PRIORITY JOURNAL; SEASONAL INFLUENZA; VIROGENESIS; VIRUS ISOLATION; VIRUS NEUTRALIZATION; ZYGOTE;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CELL LINE; CHICK EMBRYO; CROSS REACTIONS; DOGS; FEMALE; FERRETS; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; JAPAN; MALE; MIDDLE AGED; NEUTRALIZATION TESTS;

EID: 84861756876     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.05726-11     Document Type: Article

References (71)

1. Alymova IV, et al. 1998. Immunogenicity and protective efficacy in mice of influenza B virus vaccines grown in mammalian cells or embryonated chicken eggs. J. Virol. 72:4472-4477. (Pubitemid 28188760)
2. Ansaldi F, et al. 2012. Intanza(®) 15 intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses. Vaccine 30:2908-2913.
3. Arden NH, et al. 1986. Safety and immunogenicity of a 45-microgram supplemental dose of inactivated split-virus influenza B vaccine in the elderly. J. Infect. Dis. 153:805-806. (Pubitemid 16133767)
4. Beare AS, Kendal AP, Cox NJ, Scholtissek C. 1980. Human trials with wild-type H1N1 and recombinant H3N2-H1N1 influenza A viruses of 1977-1978. Infect. Immun. 28:753-761. (Pubitemid 10122499)
5. Beare AS, Schild GC, Craig JW. 1975. Trials in man with live recombinants made from A/PR/8/34 (H0 N1) and wild H3 N2 influenza viruses. Lancet ii:729-732.
6. Belshe RB, et al. 2007. Live attenuated versus inactivated influenza vaccine in infants and young children. N. Engl. J. Med. 356:685-696.
7. Beyer WE, et al. 1990. Effect of immunomodulator thymopentin on impaired seroresponse to influenza vaccine in patients on haemodialysis. Nephron 54:296-301. (Pubitemid 20097869)
8. Camilloni B, et al. 2010. An influenza B outbreak during the 2007/2008 winter among appropriately immunized elderly people living in a nursing home. Vaccine 28:7536-7541.
9. Chen Z, Aspelund A, Jin H. 2008. Stabilizing the glycosylation pattern of influenza B hemagglutinin following adaptation to growth in eggs. Vaccine 26:361-371.
10. Chen Z, et al. 2000. Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase. Vaccine 18:3214-3222. (Pubitemid 30408197)
11. Committee for Medicinal Products for Human Use (CHMP). 1997. Note for guidance on harmonization of requirements for influenza vaccines. European Agency for the Evaluation of Medicinal Products, Brussels, Belgium.
12. Couch RB, Douglas RG, Jr, Fedson DS, Kasel JA. 1971. Correlated studies of a recombinant influenza-virus vaccine. 3. Protection against experimental influenza in man. J. Infect. Dis. 124:473-480.
13. de Jong JC, Beyer WE, Palache AM, Rimmelzwaan GF, Osterhaus AD. 2000. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccineinduced antibody response to this strain in the elderly. J. Med. Virol. 61:94-99. (Pubitemid 30191232)
14. Deshpande N, et al. 2005. The RCSB Protein Data Bank: a redesigned query system and relational database based on the mmCIF schema. Nucleic Acids Res. 33:D233-D237. (Pubitemid 40207868)
15. Fleury D, Wharton SA, Skehel JJ, Knossow M, Bizebard T. 1998. Antigen distortion allows influenza virus to escape neutralization. Nat. Struct. Biol. 5:119-123.
16. Gambaryan AS, Robertson JS, Matrosovich MN. 1999. Effects of eggadaptation on the receptor-binding properties of human influenza A and B viruses. Virology 258:232-239. (Pubitemid 29390232)
17. Gorse GJ, et al. 1995. Increased anti-influenza A virus cytotoxic T cell activity following vaccination of the chronically ill elderly with live attenuated or inactivated influenza virus vaccine. J. Infect. Dis. 172:1-10.
18. Greenberg SB, Couch RB, Kasel JA. 1974. An outbreak of an influenza type A variant in a closed population: the effect of homologous and heterologous antibody on infection and illness. Am. J. Epidemiol. 100:209-215.
19. Gubareva LV, et al. 1994. Codominant mixtures of viruses in reference strains of influenza virus due to host cell variation. Virology 199:89-97. (Pubitemid 24170427)
20. Hannoun C, Megas F, Piercy J. 2004. Immunogenicity and protective efficacy of influenza vaccination. Virus Res. 103:133-138. (Pubitemid 38649072)
21. Hardy CT, Young SA, Webster RG, Naeve CW, Owens RJ. 1995. Egg fluids and cells of the chorioallantoic membrane of embryonated chicken eggs can select different variants of influenza A (H3N2) viruses. Virology 211:302-306.
22. Hobson D, Curry RL, Beare AS, Ward-Gardner A. 1972. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg. (Lond.) 70:767-777.
23. Imai M, Sugimoto K, Okazaki K, Kida H. 1998. Fusion of influenza virus with the endosomal membrane is inhibited by monoclonal antibodies to defined epitopes on the hemagglutinin. Virus Res. 53:129-139. (Pubitemid 28127850)
24. Iorio AM, et al. 2006. An influenza A/H3 outbreak during the 2004/2005 winter in elderly vaccinated people living in a nursing home. Vaccine 24:6615-6619.
25. Ito T, et al. 2000. Recognition of N-glycolylneuraminic acid linked to galactose by the alpha2,3 linkage is associated with intestinal replication of influenza A virus in ducks. J. Virol. 74:9300-9305.
26. Katz JM, Wang M, Webster RG. 1990. Direct sequencing of the HA gene of influenza (H3N2) virus in original clinical samples reveals sequence identity with mammalian cell-grown virus. J. Virol. 64:1808-1811. (Pubitemid 20104920)
27. Katz JM, Webster RG. 1992. Amino acid sequence identity between the HA1 of influenza A (H3N2) viruses grown in mammalian and primary chick kidney cells. J. Gen. Virol. 73(Pt 5):1159-1165.
28. Katz JM, Webster RG. 1989. Efficacy of inactivated influenza A virus (H3N2) vaccines grown in mammalian cells or embryonated eggs. J. Infect. Dis. 160:191-198. (Pubitemid 19189009)
29. Kida H, Brown LE, Webster RG. 1982. Biological activity of monoclonal antibodies to operationally defined antigenic regions on the hemagglutinin molecule of A/Seal/Massachusetts/1/80 (H7N7) influenza virus. Virology 122:38-47. (Pubitemid 12004497)
30. Kilbourne ED, et al. 1993. Influenza A virus haemagglutinin polymorphism: pleiotropic antigenic variants of A/Shanghai/11/87 (H3N2) virus selected as high yield reassortants. J. Gen. Virol. 74(Pt 7):1311-1316. (Pubitemid 23230247)
31. Kilbourne ED, Murphy JS. 1960. Genetic studies of influenza viruses. I. Viral morphology and growth capacity as exchangeable genetic traits. Rapid in ovo adaptation of early passage Asian strain isolates by combination with PR8. J. Exp. Med. 111:387-406.
32. Labute P. 2008. The generalized Born/volume integral implicit solvent model: estimation of the free energy of hydration using London dispersion instead of atomic surface area. J. Comput. Chem. 29:1693-1698.
33. Larson HE, Tyrrell DA, Bowker CH, Potter CW, Schild GC. 1978. Immunity to challenge in volunteers vaccinated with an inactivated current or earlier strain of influenza A(H3N2). J. Hyg. (Lond.) 80:243-248. (Pubitemid 8310425)
34. Legrand J, Vergu E, Flahault A. 2006. Real-time monitoring of the influenza vaccine field effectiveness. Vaccine 24:6605-6611. (Pubitemid 46127433)
35. Lu B, Zhou H, Chan W, Kemble G, Jin H. 2006. Single amino acid substitutions in the hemagglutinin of influenza A/Singapore/21/04 (H3N2) increase virus growth in embryonated chicken eggs. Vaccine 24:6691-6693. (Pubitemid 46107169)
36. Marcelin G, et al. 2011. A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus. PLoS One 6:e26335. doi:10.1371/journal.pone.0026335.
37. Medeiros R, Escriou N, Naffakh N, Manuguerra JC, van der Werf S. 2001. Hemagglutinin residues of recent human A(H3N2) influenza viruses that contribute to the inability to agglutinate chicken erythrocytes. Virology 289:74-85. (Pubitemid 33016239)
38. Meiklejohn G, Kempe CH, Thalman WG, Lennette EH. 1952. Evaluation of monovalent influenza vaccines. II. Observations during an influenza a-prime epidemic. Am. J. Hyg. (Lond.) (55):12-21.
39. Meyer WJ, et al. 1993. Influence of host cell-mediated variation on the international surveillance of influenza A (H3N2) viruses. Virology 196:130-137.
40. Morris JA, Kasel JA, Saglam M, Knight V, Loda FA. 1966. Immunity to influenza to antibody levels. N. Engl. J. Med. 274:527-535.
41. Murphy BR, Coelingh K. 2002. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol. 15:295-323. (Pubitemid 34651533)
42. Muyanga J, et al. 2001. Antigenic and genetic analyses of influenza B viruses isolated in Lusaka, Zambia in 1999. Arch. Virol. 146:1667-1679. (Pubitemid 32925912)
43. Nakagawa N, Kubota R, Maeda A, Okuno Y. 2004. Influenza B virus Victoria group with a new glycosylation site was epidemic in Japan in the 2002-2003 season. J. Clin. Microbiol. 42:3295-3297. (Pubitemid 38938095)
44. Nichol KL. 2009. Challenges in evaluating influenza vaccine effectiveness and the mortality benefits controversy. Vaccine 27:6305-6311.
45. Nobusawa E, Ishihara H, Morishita T, Sato K, Nakajima K. 2000. Change in receptor-binding specificity of recent human influenza A viruses (H3N2): a single amino acid change in hemagglutinin altered its recognition of sialyloligosaccharides. Virology 278:587-596. (Pubitemid 32012792)
46. Oh DY, Barr IG, Mosse JA, Laurie KL. 2008. MDCK-SIAT1 cells show improved isolation rates for recent human influenza viruses compared to conventional MDCK cells. J. Clin. Microbiol. 46:2189-2194.
47. Okuno Y, Isegawa Y, Sasao F, Ueda S. 1993. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J. Virol. 67:2552-2558. (Pubitemid 23118850)
48. Onufriev A, Bashford D, Case DA. 2000. Modification of the generalized Born model suitable for macromolecules. J. Phys. Chem. B 104:3712-3720.
49. Pekosz A, Newby C, Bose PS, Lutz A. 2009. Sialic acid recognition is a key determinant of influenza A virus tropism in murine trachea epithelial cell cultures. Virology 386:61-67.
50. Pereira MS, Chakraverty P, Schild GC, Coleman MT, Dowdle WR. 1972. Prevalence of antibody to current influenza viruses and effect of vaccination on antibody response. Br. Med. J. 4:701-703.
51. Ponder JW, Case DA. 2003. Force fields for protein simulations. Adv. Protein Chem. 66:27-85. (Pubitemid 37392314)
52. Potter CW, Jennings R, Nicholson K, Tyrrell DA, Dickinson KG. 1977. Immunity to attenuated influenza virus WRL 105 infection induced by heterologous, inactivated influenza A virus vaccines. J. Hyg. (Lond.) 79:321-332.
53. Potter CW, Oxford JS. 1979 Determinants of immunity to influenza infection in man. Br. Med. Bull. 35:69-75. (Pubitemid 9096975)
54. Robertson JS, et al. 1987. Structural changes in the haemagglutinin which accompany egg adaptation of an influenza A(H1N1) virus. Virology 160:31-37. (Pubitemid 17138819)
55. Robertson JS, et al. 1985. Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs. Virology 143:166-174. (Pubitemid 15113230)
56. Saito T, et al. 2004. Antigenic alteration of influenza B virus associated with loss of a glycosylation site due to host-cell adaptation. J. Med. Virol. 74:336-343. (Pubitemid 39150402)
57. Sandbulte MR, et al. 2007. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med. 4:e59. doi:10.1371/journal.pmed.0040059.
58. Shaw MW, et al. 2002. Reappearance and global spread of variants of influenza B/Victoria/2/87 lineage viruses in the 2000-2001 and 2001-2002 seasons. Virology 303:1-8. (Pubitemid 36027160)
59. Shirakawa K, et al. 2008. Phosphorylation of APOBEC3G by protein kinase A regulates its interaction with HIV-1 Vif. Nat. Struct. Mol. Biol. 15:1184-1191.
60. Song H, et al. 2007. A single amino acid of the human immunodeficiency virus type 2 capsid affects its replication in the presence of cynomolgus monkey and human TRIM5alphas. J. Virol. 81:7280-7285. (Pubitemid 46986664)
61. Stevens J, et al. 2010. Receptor specificity of influenza A H3N2 viruses isolated in mammalian cells and embryonated chicken eggs. J. Virol. 84:8287-8299.
62. Szilagyi PG, et al. 2008. Influenza vaccine effectiveness among children 6 to 59 months of age during 2 influenza seasons: a case-cohort study. Arch. Pediatr. Adolesc. Med. 162:943-951.
63. Throsby M, et al. 2008. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3:e3942. doi:10.1371/journal.pone.0003942.
64. Tung CS, Goodman JL, Lu H, Macken CA. 2004. Homology model of the structure of influenza B virus HA1. J. Gen. Virol. 85:3249-3259. (Pubitemid 39445442)
65. Vajo Z, Tamas F, Jankovics I. 2012. A reduced-dose seasonal trivalent influenza vaccine is safe and immunogenic in adult and elderly patients in a randomized controlled trial. Clin. Vaccine Immunol. 19:313-318.
66. Vines A, et al. 1998. The role of influenza A virus hemagglutinin residues 226 and 228 in receptor specificity and host range restriction. J. Virol. 72:7626-7631. (Pubitemid 28377900)
67. Wang Q, Cheng F, Lu M, Tian X, Ma J. 2008. Crystal structure of unliganded influenza B virus hemagglutinin. J. Virol. 82:3011-3020. (Pubitemid 351329189)
68. World Health Organization. 2011.Summaryof status of development and availability of influenza B candidate vaccine viruses and potency testing reagents. World Health Organization, Geneva, Switzerland.
69. World Health Organization. 2009. Recommended composition of influenza virus vaccines for use in the 2009-2010 influenza season. World Health Organization, Geneva, Switzerland.
70. World Health Organization. 2010. Recommended composition of influenza virus vaccines for use in the 2010-2011 northern hemisphere influenza season. World Health Organization, Geneva, Switzerland.
71. Xie H, et al. 2011. Immunogenicity and cross-reactivity of 2009-2010 inactivated seasonal influenza vaccine in US adults and elderly. PLoS One 6:e16650. doi:10.1371/journal.pone.0016650.